-
-
-
-
-
-
-
LifeSci Capital Downgrades Akero Therapeutics (AKRO) to Market Perform
-
-
-
-
-
-
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) Announces Proposed Public Offering of Common Stock
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Akero Therapeutics (AKRO)
-
-
-
-
-
-
-
Akero Therapeutics (AKRO) to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD
-
-
-
-
-
409,092 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

